merged_alzheimers-treatment-kisunla-donanemab.txt
<other>I will analyze the article to answer each question based solely on the information provided.</other>

<question_number>1</question_number>
<answer>N/A</answer>

<other>The article mentions multiple reasons for skepticism including safety risks and modest benefits, but doesn't identify one primary reason.</other>

<question_number>2</question_number>
<answer>Might discourage patients from participating in trials for treatments that could be better and is slowing progress</answer>

<question_number>3</question_number>
<answer>There's no correlation in any of their studies between the removal of amyloid plaques and the clinical response in individual subjects</answer>

<question_number>4</question_number>
<answer>N/A</answer>

<other>The article states higher rates occurred but doesn't discuss the impact on perception of safety.</other>

<question_number>5</question_number>
<answer>The expectation that patients can stop Kisunla after their plaques are cleared</answer>

<question_number>6</question_number>
<answer>Might discourage patients from participating in trials for treatments that could be better</answer>

<question_number>7</question_number>
<answer>Kisunla is given monthly while Leqembi is given every two weeks, and patients can stop Kisunla after amyloid is cleared</answer>

<question_number>8</question_number>
<answer>Amyloid</answer>

<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>

<question_number>10</question_number>
<answer>Trial participants with intermediate tau levels declined more slowly on donanemab than those with high levels</answer>